ClinicalTrials.gg
RecruitingNCT06637644Updated Oct 15, 2024

Impella RP Flex with Smart Assist

An observational study in Right Ventricular (RV) Dysfunction, sponsored by Abiomed Inc.. Recruiting at 31 sites in United States. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Abiomed Inc. (part of Johnson & Johnson) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

To capture observational data of the Abiomed Impella RP Flex in a real-world setting.

02

Conditions studied

  • Right Ventricular (RV) Dysfunction
03

In context

Lead sponsor

Abiomed Inc. is the lead sponsor of 34 studies on the registry; 5 are open to participants now.

First submitted after Abiomed Inc. became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study includes sites from the US

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who received mechanical circulatory support (MCS) with an Impella RP Flex will be considered eligible for the registry.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Patients implanted with right-sided ventricular assist device

    Device: Right-sided ventricular assist device

Interventions

  • DeviceRight-sided ventricular assist device

    Percutaneous device for right heart support

06

What researchers measure

Primary outcomes

  1. Objectives

    Survival at hospital discharge, with follow-ups at 30 days, 90 days, and 1-year post-discharge of Impella RP patients from real-world surveillance data.

    Time frame: 1 year post implant

07

Study locations

31 of 31 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Apr 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2024
First posted
Oct 15, 2024
StartActual
May 29, 2024
Primary completionEst.
Apr 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06637644
Lead sponsor
Abiomed Inc.
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
May 29, 2024
Primary completion
Apr 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Oct 15, 2024

Study contacts

Stacie Hallaway, Sr. Clinical Project Manager
Contact
shallawa@its.jnj.com
839-216-3087

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion